Johnson & Johnson (NYSE:JNJ) Given “Hold” Rating at Bank of America

Share on StockTwits

Bank of America reissued their hold rating on shares of Johnson & Johnson (NYSE:JNJ) in a research note released on Tuesday morning, AnalystRatings.com reports. The firm currently has a $150.00 price objective on the stock.

Other analysts have also issued reports about the stock. BMO Capital Markets assumed coverage on shares of Yelp in a research report on Wednesday, April 17th. They issued an outperform rating on the stock. Barclays raised their target price on shares of from GBX 200 ($2.61) to GBX 210 ($2.74) and gave the stock an equal weight rating in a research report on Friday, June 21st. Wells Fargo & Co raised their target price on shares of Wingstop from $76.00 to $84.00 and gave the stock an outperform rating in a research report on Monday, May 6th. Morgan Stanley set a $60.00 target price on shares of Berry Global Group and gave the stock a hold rating in a research report on Wednesday, April 17th. Finally, Credit Suisse Group set a $92.00 target price on shares of Ashland Global and gave the stock a buy rating in a research report on Friday, July 12th. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Johnson & Johnson presently has a consensus rating of Buy and a consensus price target of $148.56.

JNJ stock opened at $132.07 on Tuesday. The firm has a 50 day simple moving average of $138.36. The firm has a market capitalization of $350.10 billion, a price-to-earnings ratio of 16.15, a PEG ratio of 2.28 and a beta of 0.70. Johnson & Johnson has a 12 month low of $121.00 and a 12 month high of $148.99. The company has a quick ratio of 1.13, a current ratio of 1.44 and a debt-to-equity ratio of 0.47.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 16th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.42 by $0.16. The business had revenue of $20.56 billion for the quarter, compared to analyst estimates of $20.39 billion. Johnson & Johnson had a net margin of 20.08% and a return on equity of 38.57%. The company’s quarterly revenue was down 1.3% on a year-over-year basis. During the same period in the prior year, the business earned $2.10 earnings per share. Sell-side analysts expect that Johnson & Johnson will post 8.59 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be given a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, August 26th. This represents a $3.80 dividend on an annualized basis and a yield of 2.88%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 46.45%.

In other news, Director Marillyn A. Hewson bought 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 11th. The shares were purchased at an average price of $139.68 per share, for a total transaction of $419,040.00. Following the completion of the transaction, the director now owns 3,000 shares in the company, valued at $419,040. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.23% of the stock is currently owned by company insiders.

A number of large investors have recently bought and sold shares of the business. Livforsakringsbolaget Skandia Omsesidigt raised its stake in Johnson & Johnson by 1.2% during the second quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 129,264 shares of the company’s stock worth $18,004,000 after purchasing an additional 1,530 shares during the period. Well Done LLC raised its stake in Johnson & Johnson by 6.6% during the second quarter. Well Done LLC now owns 11,778 shares of the company’s stock worth $1,640,000 after purchasing an additional 731 shares during the period. Parisi Gray Wealth Management raised its stake in Johnson & Johnson by 1.7% during the second quarter. Parisi Gray Wealth Management now owns 10,519 shares of the company’s stock worth $1,465,000 after purchasing an additional 173 shares during the period. Eqis Capital Management Inc. raised its stake in Johnson & Johnson by 12.8% during the second quarter. Eqis Capital Management Inc. now owns 21,446 shares of the company’s stock worth $2,987,000 after purchasing an additional 2,428 shares during the period. Finally, Moors & Cabot Inc. raised its stake in Johnson & Johnson by 2.5% during the second quarter. Moors & Cabot Inc. now owns 122,997 shares of the company’s stock worth $17,135,000 after purchasing an additional 2,955 shares during the period. 66.85% of the stock is currently owned by institutional investors.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: Dow Jones Industrial Average (DJIA)

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.